Volume 121, Issue 2, Pages (August 2001)

Slides:

Advertisements

Similar presentations

Celiac disease–like abnormalities in a subgroup of patients with irritable bowel syndrome Ulrich Wahnschaffe, R. Ullrich, E.O. Riecken, J.D. Schulzke Gastroenterology.

Advertisements

Serum immunoglobulin a from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation Tuula Halttunen, Markku Mäki.

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease Richard N. Fedorak, *, Alfred Gangl, ‡, Charles.

Volume 120, Issue 6, Pages (May 2001)

Volume 134, Issue 7, Pages (June 2008)

Volume 123, Issue 4, Pages (October 2002)

Volume 120, Issue 3, Pages (February 2001)

Anti–tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report Philip V. Hassard, Scott W. Binder, Viera.

Volume 135, Issue 4, Pages (October 2008)

Diagnosis of irritable bowel syndrome

Volume 119, Issue 2, Pages (August 2000)

Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol Peter A.L. Bonis, Marshall Kaplan

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Polyxeni Koutkia, Zhiren Lu, Tai C. Chen, Michael F. Holick

Psychiatric disorders among veterans with hepatitis C infection

Volume 117, Issue 2, Pages (August 1999)

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease Stephen B Hanauer, Carrie L Wagner,

Volume 130, Issue 4, Pages (April 2006)

A Randomized, Double-Blind, Placebo-Controlled Trial of Nutritional Supplementation During Acute Illness Salah Gariballa, MD, Sarah Forster, MSc, Stephen.

Effect of the Prebiotic Oligofructose on Relapse of Clostridium difficile-Associated Diarrhea: A Randomized, Controlled Study Stephen Lewis, Stephen.

Appendectomy is followed by increased risk of Crohn's disease

Volume 134, Issue 7, Pages (June 2008)

Volume 123, Issue 4, Pages (October 2002)

Volume 153, Issue 1, Pages e6 (July 2017)

Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double- blind, placebo-controlled trials Stephen B Hanauer, Ulf Strömberg

Volume 115, Issue 1, Pages (July 1998)

Volume 120, Issue 3, Pages (February 2001)

Antje Timmer*, Lloyd R. Sutherland*,‡, Francois Martin§

Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease Elana A. Maser, Renata Villela,

Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection

Volume 130, Issue 2, Pages (February 2006)

Volume 120, Issue 4, Pages (March 2001)

Volume 123, Issue 3, Pages (September 2002)

Volume 123, Issue 2, Pages (August 2002)

Ronnie Fass, Stephen J. Sontag, Barry Traxler, Mark Sostek

Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy.

Volume 132, Issue 5, Pages (May 2007)

Volume 119, Issue 6, Pages (December 2000)

Volume 119, Issue 6, Pages (December 2000)

Volume 132, Issue 1, Pages (January 2007)

Brian G. Feagan, Gordon R. Greenberg, Gary Wild, Richard N

Volume 122, Issue 7, Pages (June 2002)

David H. Bruining, William J. Sandborn

Lise L. Kjaergard, Sarah L. Frederiksen, Christian Gluud

AGA technical review on nonalcoholic fatty liver disease

Volume 141, Issue 5, Pages (November 2011)

Antibody-mediated gastrointestinal dysmotility in scleroderma

Volume 114, Issue 6, Pages (June 1998)

Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease Gerassimos J.

Psychiatric disorders among veterans with hepatitis C infection

Volume 121, Issue 5, Pages (November 2001)

Volume 126, Issue 2, Pages (February 2004)

The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double.

Volume 121, Issue 5, Pages (November 2001)

Chronic Diarrhea Clinical Gastroenterology and Hepatology

Volume 116, Issue 5, Pages (May 1999)

AGA technical review on osteoporosis in gastrointestinal diseases

Volume 117, Issue 4, Pages (October 1999)

Serum ferritin levels in West Nile encephalitis

Volume 117, Issue 3, Pages (September 1999)

Volume 122, Issue 4, Pages (April 2002)

Volume 128, Issue 7, Pages (June 2005)

Volume 126, Issue 4, Pages (April 2004)

Mesalamine and relapse prevention in Crohn's disease

A Randomized, Double-Blind, Placebo-controlled Study of Growth Hormone in the Treatment of Fibromyalgia 1 Robert M Bennett, Sharon C Clark, Jacqueline.

Volume 121, Issue 4, Pages (October 2001)

Predictors of response to infliximab in patients with Crohn's disease

Medical Therapy for Refractory Pediatric Crohn’s Disease

Assessing activity of pediatric Crohn's disease: Which index to use?

(A) Percentage of patients achieving remission or response at week 12 or 24 after initiating ova therapy. (A) Percentage of patients achieving remission.

Presentation transcript:

Volume 121, Issue 2, Pages 268-274 (August 2001) A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active crohn's disease Fiona H. Gordon, Clement W.Y. Lai, Mark I. Hamilton, Miles C. Allison, Emmanuel D. Srivastava, Marilyn G. Fouweather, Stephen Donoghue, Carol Greenlees, Javaid Subhani, Peter L. Amlot, Roy E. Pounder Gastroenterology Volume 121, Issue 2, Pages 268-274 (August 2001) DOI: 10.1053/gast.2001.26260 Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig.1 Trial profile of patients with mild to moderately active Crohn's disease who received 3 mg/kg natalizumab or placebo by double-blind randomization. Gastroenterology 2001 121, 268-274DOI: (10.1053/gast.2001.26260) Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig.2 Mean CDAI by patient group (LOCF data), weeks 0–4.Bars indicate SD, and numbers above and below indicate number of patients in each group who had begun receiving rescue therapy. Gastroenterology 2001 121, 268-274DOI: (10.1053/gast.2001.26260) Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig.3 Clinical status of patients 2 weeks after a single infusion of 3 mg/kg natalizumab or placebo at 2 weeks postinfusion.Observed differences between groups are not significant. Gastroenterology 2001 121, 268-274DOI: (10.1053/gast.2001.26260) Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig.4 Mean serum natalizumab concentrations of 18 patients after a single 3-mg/kg infusion.Bars indicate SD. Gastroenterology 2001 121, 268-274DOI: (10.1053/gast.2001.26260) Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig.5 Mean lymphocyte counts of patients with Crohn's disease after a single infusion of 3 mg/kg natalizumab (n = 18) or placebo (n = 12).Bars indicate SD. Gastroenterology 2001 121, 268-274DOI: (10.1053/gast.2001.26260) Copyright © 2001 American Gastroenterological Association Terms and Conditions